Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

S&P Biotech SPDR (NY: XBI )

99.85 -0.15 (-0.15%)
Streaming Delayed Price Updated: 10:55 AM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about S&P Biotech SPDR

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF
On Friday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE: 
Via Benzinga
Topics Stocks
Exposures US Equities
Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI 
Via Benzinga
Topics Stocks
Exposures US Equities
Unusual Options Activity Insight: SPDR Series Trust SPDR S&P Biotech ETF
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE: XBI) saw some unusual options activity... 
Via Benzinga
Topics Stocks
Exposures US Equities
Analyzing SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
On Thursday, shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw unusual options activity. After the option alert, the stock price moved up to $126.24. Sentiment... 
Via Benzinga
Topics Stocks
Exposures US Equities
Understanding SPDR Series Trust SPDR S&P Biotech ETF's Unusual Options Activity
Shares of SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) saw some unusual options activity on Monday. Following the unusual option alert, the stock price moved down to $132... 
Via Benzinga
Topics Stocks
Exposures US Equities
A Fresh Dose of Biotech Perspective
If the only thing that’s changed with your favorite biotech is the price, stay the course. Your bottom line will thank you for it later. 
Via Talk Markets
Mid-Cap Biotech Picks: Seasonal Rally Underway
Many Mid-Cap biotech stocks were hit hard after the February peak. We suggest three new mid-cap biotech picks. All three picks can be volatile but very tradable. 
Via Talk Markets
IBB Vs. XBI: Which Biotech ETF Has A Better Chart?
The SPDR S&P Biotech ETF XBI is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF IBB has broken out. 
Via Talk Markets
Topics Stocks
Exposures US Equities
IBB Vs. XBI: Which Biotech ETF Has A Better Chart?
The SPDR S&P Biotech ETF (NYSE: XBI) is trading below an important resistance level, but the iShares Nasdaq Biotechnology ETF (NASDAQ: IBB) has broken out. Resistance is a... 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Regeneron Pharmaceuticals Analyst Says Competitive Concerns Are Overblown, Pipeline Opportunity Underappreciated
Regeneron Pharmaceuticals Inc.'s (NASDAQ:REGN) robust ... 
Via Benzinga
Healthcare Portfolio Playbook: Time To Rebalance With MedTech
As we look to re-balance our portfolio in the near-term, investors should consider adding Medtech as we have suggested in the past. Though, more recently, we have also focused on large-cap... 
Via Talk Markets
Should You Buy Biotech ETFs Now?
Instead of trying to pick winners in this volatile space, it is better to invest in broader biotech ETFs that stand to benefit from increased investor interest and rising spending on drugs and... 
Via Talk Markets
Tuesday Talk: Action!
U.S. stock markets started the week in continued action mode. The S&P 500 closed at 4,255, up nearly 8 points, the Dow closed at 34,394, down 85 points and the Nasdaq Composite closed at 14,174, up... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Biotechs Ready To Roar
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
Exposures Product Safety
3 Biotech ETFs That Could Double Your Money by 2025 With Zero Effort
In a sector where picking individual stocks is a high-risk, high-reward strategy, the diversification of exchange-traded funds can be highly appealing. 
Via The Motley Fool
Analyzing SPDR Series Trust SPDR S&amp;P Biotech ETF's Unusual Options Activity
SPDR Series Trust SPDR S&P Biotech ETF (NYSE:XBI) shares experienced unusual options activity on Friday. The stock price moved up to $136.19 following the option alert.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Leisure & Entertainment ETF (PEJ) and AMC Networks (AMCX) Caught In Meme Madness
Dynamic Leisure and Entertainment ETF (PEJ) has been by far the best performer over the past week. 
Via Talk Markets
Stocks Drop On Turnaround Tuesday As The Next Leg Lower May Have Begun
It was not a good day for the Russell 2000. After failing to break out yesterday, it fell sharply today. 
Via Talk Markets
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
Medical Miracles Inside Biotech ETFs
The events of the past year focused a lot of attention on game changing developments made possible by the global biotech industry. Of the major names Moderna is the one where the original research and... 
Via Talk Markets
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Buy This Instead Of "Big Tech" Stocks And Bank 55% Gains
Investors are bobbing laterally from sector to sector, searching for stocks to buy ahead of a traditional summer slowdown that could be made worse by worries about inflation. 
Via Talk Markets
5 All-Star ETFs & Stocks to Buy on the Dip
Here are the five ETFs that are currently undervalued and could generate solid returns in a rising stock market, and five stocks that are cheap and have the potential to deliver higher returns 
Via Talk Markets
How To Profit In A $29 Billion “New Biotech” Sector
Drug market companies haven’t exactly hit the S&P 500 yet; we’re still in “ground floor” territory. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Biotech ETFs To Suffer As US Backs IP Waiver For COVID-19 Vaccines
The Biden administration announced support for the waiver of intellectual property protections for COVID-19 vaccines proposed by South Africa and India. Let’s take a look at ETFs that can suffer from... 
Via Talk Markets
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Buying This Beaten-Down ETF Could Make You a Fortune Over the Next 10 Years
It definitely made investors a lot of money over the last decade. And its future could be brighter than the past. 
Via The Motley Fool
Jon Najarian Sees Unusual Option Activity In SPDR S&P Biotech ETF And Verra Mobility
On CNBC's "Fast Money Halftime Report," Jon Najarian gave some unusual options activity plays. Najarian sees unusual activity in: SPDR S&P Biotech ETF (NYSE:... 
Via Benzinga
Topics Stocks
Exposures US Equities
2 Must-Own Biotech Stocks To Buy In May
After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks such as Gilead Sciences... 
Via Talk Markets
AskSlim Market Week - Friday, April 30
This video provides technical analysis, cycle analysis, and commentary regarding the movement in the markets throughout the past week. 
Via Talk Markets
Best Biotech Stocks & ETFs for mRNA, Gene Editing
2020 was the most challenging year in decades but it was great for scientific innovation, particularly in the biotech space. 
Via Talk Markets
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.